Natural Product (NP) Details
| General Information of the NP (ID: NP6396) | |||||
|---|---|---|---|---|---|
| Name |
Ulinastatin
|
||||
| Synonyms |
Urinastatin; Urinary trypsin inhibitor; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-31-6; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor (human urine urinastatin protein moiety); 80449-32-7; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Miraclid; AC1L2Y1N; UTI68; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; AC1Q70L4; AKOS025401879; CS-7119; MR 20 (magnetic p
Click to Show/Hide
|
||||
| Species Origin | Homo sapiens ... | Click to Show/Hide | |||
| Homo sapiens | |||||
| Disease | Preterm labour/delivery [ICD-11: JB00] | Phase 3 | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.485
MDCK Permeability
-4.607
PAMPA
-
HIA
- - -
Distribution
VDss
0.049
PPB
90.3%
BBB
+++
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
++
CYP2C19 inhibitor
+++
CYP2C19 substrate
+++
CYP2C9 inhibitor
- - -
CYP2C9 substrate
+++
CYP2D6 inhibitor
- - -
CYP2D6 substrate
+++
CYP3A4 inhibitor
- -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
+++
CYP2C8 inhibitor
- -
HLM Stability
++
Excretion
CLplasma
7.148
T1/2
0.732
Toxicity
DILI
-
Rat Oral Acute Toxicity
- -
FDAMDD
- -
Respiratory
- - -
Human Hepatotoxicity
- -
Ototoxicity
- - -
Drug-induced Nephrotoxicity
- -
Drug-induced Neurotoxicity
-
Hematotoxicity
- - -
Genotoxicity
- - -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C13H16O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1CC2(CC=C1)COC(OC2)C3=CC=CO3
|
||||
| InChI |
1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2
|
||||
| InChIKey |
ODVKSTFPQDVPJZ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 80449-31-6
|
||||
| Herb ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | WNT3A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
UTI enhanced the 5-FU sensitivity of HCC cells by attenuating their stemness via inhibiting Wnt/Beta-catenin signaling. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Trypsin-1 (PRSS1) | Molecule Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
| 2 | Pancreatic secretion | |||
| 3 | Protein digestion and absorption | |||
| 4 | Influenza A | |||
| Reactome | Activation of Matrix Metalloproteinases | Click to Show/Hide | ||
| 2 | Cobalamin (Cbl, vitamin B12) transport and metabolism | |||
| WikiPathways | Activation of Matrix Metalloproteinases | Click to Show/Hide | ||